Kinnate Biopharma Inc. (KNTE)

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HireRight will receive (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a.

Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.

SAN FRANCISCO, SAN DIEGO and CASTRES, France, March 01, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, and Pierre Fabre Médicament, SAS (“Pierre Fabre Laboratories”), a global player in oncology, today announced their agreement to the sale of the Company's investigational pan-RAF inhibitor, exarafenib, and other pan-RAF program assets pursuant to the APA entered into by the parties. The sale of global rights is in furtherance of the Company's previously announced exploration of strategic alternatives.

Kinnate Biopharma Inc. (KNTE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kinnate Biopharma Inc. (NasdaqGS: KNTE) to XOMA Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HireRight will receive (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a.

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kinnate Biopharma Inc. (NASDAQ: KNTE) and its board of directors concerning the proposed acquisition of the company by XOMA Corporation. Stockholders will receive between $2.3352 and $2.5879, as well as one contingent value right, for each share of Kinnate Biopharma stock that they hold.

MILWAUKEE , Feb. 16, 2024 /PRNewswire/ -- Ademi LLP is investigating Kinnate (Nasdaq: KNTE) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA. Click here to learn how to join the https://www.ademilaw.com/case/kinnate-biopharma-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Kinnate Biopharma Inc. (NASDAQ: KNTE) to XOMA Corporation is fair to Kinnate shareholders. Under the terms of the proposed transaction, XOMA would acquire Kinnate for (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a non-transferable contingent value right, representing the right to recei.

SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby XOMA Corporation ("XOMA") will acquire Kinnate for a price per share of Kinnate common stock ("Kinnate common stock") of between $2.3352 and $2.5879 in cash, consisting of (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of up to $0.2527 per share, plus one non-transferable contingent value right per share, representing the right to receive (a) 100% of the net proceeds payable from any disposition of the Company's investigational pan-RAF inhibitor, exarafenib, and/or any other pan-RAF inhibitors prior to the closing of the merger transaction and (b) 85% of the net proceeds payable from any disposition of other Kinnate assets entered into prior to, or within one year from, closing and received within five years of closing pursuant to a definitive contingent value rights agreement.

SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced financial results for the third quarter of 2023 and recent corporate updates.

Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.

SAN FRANCISCO and SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based on a strategic review of its business.

SAN FRANCISCO and SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will participate in two upcoming investor conferences:

While your friendly financial advisor will probably never recommend these terribly risky enterprises, sometimes, you're just in the mood for stocks with 100% upside potential. And with these ideas, you're going to get that and more, assuming the stars align correctly.

Insiders think these are penny stocks to buy based on recent filings but are they worth the risk? The post 4 Penny Stocks To Buy According To Insiders This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that a clinical trial abstract for its investigational pan-RAF inhibitor exarafenib has been selected for an oral presentation during the Clinical Trials Mini Symposium Session at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19 in Orlando, Fla.